Randolph Corteling | Head Of Research
ReNeuron Group Plc

Randolph Corteling, Head Of Research, ReNeuron Group Plc

I started my career as a Research associate at Novartis, before undertaking a PhD in Medical and Surgical Sciences at Nottingham University. I then subsequently spent 3 years as a Heart and Stroke Foundation postdoctoral fellow at the University Calgary, Canada before joining ReNeuron as a senior member of the research team in 2007. During my time at ReNeuron, I have developed a number of new discoveries along with a thorough understanding of stem cell biology leading to my appointment as Head of Cell Biology in 2011 before subsequently being made Head of Research in April 2015.

Appearances:



Conference Day 2 - Wednesday 1st April 2020 @ 11:40

An Exosome-based Drug Delivery Platform Derived from a Human Neural Stem Cell (hNSC) Line

  • To ensure the scale required for clinical research and commercialisation producer cell immortalisation and clonal isolation is a practical strategy to produce consistent, functionally bioactive exosomes for use as therapeutic agents.
  • The cell line can be rapidly modified to alter exosome cargo or reprogrammed to change its phenotype while maintaining its conditional immortalisation.
  • hNSC derived exosomes demonstrate favourable distribution across the blood brain barrier.
last published: 04/Jun/20 08:25 GMT

back to speakers